Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2023.Dec.21

Announcement that the institutional director of OBI, Sheng Cheng Investment Co., Ltd., changes its representative

2023.Dec.20

Announcement of the resignation of natural-person director

2023.Dec.20

Announcement on behalf of OBIGEN of the resignation of its institutional director

2023.Dec.20

OBI announces termination of BCVax, OBI-866, and OBI-999

2023.Dec.20

Announcement of resignation of the Chairperson

2023.Dec.20

OBI licensed the worldwide therapeutic rights of OBI-858 to OBIGEN

2023.Dec.06

Announcement on behalf of subsidiary, OBIGEN, that the Company’s board appointed internal audit officer

2023.Dec.01

OBI has filed the application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to US FDA

2023.Nov.10

OBI is invited to attend the investor conference hosted by MasterLink Securities and declare the development of all its products and future plan

2023.Nov.06

The change of the Company's business address was approved by the Board of Directors

News

Latest News

Events

Latest events